142 related articles for article (PubMed ID: 10385633)
1. The pravastatin-induced decrease of biliary cholesterol secretion is not directly related to an inhibition of cholesterol synthesis in humans.
Kallien G; Lange K; Stange EF; Scheibner J
Hepatology; 1999 Jul; 30(1):14-20. PubMed ID: 10385633
[TBL] [Abstract][Full Text] [Related]
2. Lifibrol as a model compound for a novel lipid-lowering mechanism of action.
Berthold HK; Sudhop T; von Bergmann K; Gouni-Berthold I
J Cardiovasc Pharmacol Ther; 2010 Dec; 15(4):364-72. PubMed ID: 20693157
[TBL] [Abstract][Full Text] [Related]
3. The effects of the 3-hydroxy, 3-methylglutaryl coenzyme A reductase inhibitor pravastatin on bile composition and nucleation of cholesterol crystals in cholesterol gallstone disease.
Smit JW; van Erpecum KJ; Renooij W; Stolk MF; Edgar P; Doornewaard H; Vanberge-Henegouwen GP
Hepatology; 1995 Jun; 21(6):1523-9. PubMed ID: 7768495
[TBL] [Abstract][Full Text] [Related]
4. Influence of cholesterol-lowering on plasma membrane lipids and function.
Lijnen P; Echevaría-Vázquez D; Petrov V
Methods Find Exp Clin Pharmacol; 1996 Mar; 18(2):123-36. PubMed ID: 8740244
[TBL] [Abstract][Full Text] [Related]
5. The effect of pravastatin and atorvastatin on coenzyme Q10.
Bleske BE; Willis RA; Anthony M; Casselberry N; Datwani M; Uhley VE; Secontine SG; Shea MJ
Am Heart J; 2001 Aug; 142(2):E2. PubMed ID: 11479481
[TBL] [Abstract][Full Text] [Related]
6. Pravastatin does not affect insulin sensitivity and adipocytokines levels in healthy nondiabetic patients.
Gannagé-Yared MH; Azar RR; Amm-Azar M; Khalifé S; Germanos-Haddad M; Neemtallah R; Halaby G
Metabolism; 2005 Jul; 54(7):947-51. PubMed ID: 15988706
[TBL] [Abstract][Full Text] [Related]
7. Bile acid synthesis from newly synthesized vs. preformed cholesterol precursor pools in the rat.
Scheibner J; Fuchs M; Schiemann M; Tauber G; Hörmann E; Stange EF
Hepatology; 1993 Jun; 17(6):1095-102. PubMed ID: 8514259
[TBL] [Abstract][Full Text] [Related]
8. Isotopomer spectral analysis of intermediates of cholesterol synthesis in patients with cerebrotendinous xanthomatosis.
Clarenbach JJ; Lindenthal B; Dotti MT; Federico A; Kelleher JK; von Bergmann K
Metabolism; 2005 Mar; 54(3):335-44. PubMed ID: 15736111
[TBL] [Abstract][Full Text] [Related]
9. The synergistic hypocholesterolemic activity of the potent cholesterol absorption inhibitor, ezetimibe, in combination with 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in dogs.
Davis HR; Pula KK; Alton KB; Burrier RE; Watkins RW
Metabolism; 2001 Oct; 50(10):1234-41. PubMed ID: 11586500
[TBL] [Abstract][Full Text] [Related]
10. Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.
Lilja JJ; Kivistö KT; Neuvonen PJ
Clin Pharmacol Ther; 1999 Aug; 66(2):118-27. PubMed ID: 10460065
[TBL] [Abstract][Full Text] [Related]
11. Experimental model of escape phenomenon in hamsters and the effectiveness of YM-53601 in the model.
Ugawa T; Kakuta H; Moritani H; Shikama H
Br J Pharmacol; 2002 Mar; 135(6):1572-8. PubMed ID: 11906972
[TBL] [Abstract][Full Text] [Related]
12. Differing effects of low-dose estrogen-progestin therapy and pravastatin in postmenopausal hypercholesterolemic women.
Davis SR; Goldstat R; Newman A; Berry K; Burger HG; Meredith I; Koch K
Climacteric; 2002 Dec; 5(4):341-50. PubMed ID: 12626213
[TBL] [Abstract][Full Text] [Related]
13. Does pravastatin increase chylomicron remnant catabolism in postmenopausal women with type 2 diabetes mellitus?
Ng TW; Watts GF; Stuckey BG; Ching HL; Chan DC; Uchida Y; Sakai N; Yamashita S; Martins IJ; Redgrave TG; Barrett PH
Clin Endocrinol (Oxf); 2005 Dec; 63(6):650-6. PubMed ID: 16343099
[TBL] [Abstract][Full Text] [Related]
14. Effect of withdrawal of pravastatin therapy on C-reactive protein and low-density lipoprotein cholesterol.
van der Harst P; Asselbergs FW; Hillege HL; Bakker SJ; Voors AA; van Veldhuisen DJ; van Gilst WH;
Am J Cardiol; 2007 Nov; 100(10):1548-51. PubMed ID: 17996517
[TBL] [Abstract][Full Text] [Related]
15. Changes in biliary lipid output after interruption of pravastatin treatment in humans.
Hillebrant CG; Eriksson M; Nyberg B; Einarsson K
Eur J Clin Invest; 1996 Dec; 26(12):1160-5. PubMed ID: 9013093
[TBL] [Abstract][Full Text] [Related]
16. Effects of pravastatin on cholesterol metabolism of cholesterol-fed heterozygous WHHL rabbits.
Harsch M; Gebhardt A; Reymann A; Lang G; Schliack M; Löser R; Braesen JH; Niendorf A
Br J Pharmacol; 1998 May; 124(2):277-82. PubMed ID: 9641543
[TBL] [Abstract][Full Text] [Related]
17. Rapid effect of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition on coronary endothelial function.
Wassmann S; Faul A; Hennen B; Scheller B; Böhm M; Nickenig G
Circ Res; 2003 Oct; 93(9):e98-103. PubMed ID: 14551237
[TBL] [Abstract][Full Text] [Related]
18. Effect of ezetimibe on low-density lipoprotein subtype distribution: results of a placebo-controlled, double-blind trial in patients treated by regular low-density lipoprotein apheresis and statins.
Geiss HC; Otto C; Parhofer KG
Metabolism; 2006 May; 55(5):599-604. PubMed ID: 16631435
[TBL] [Abstract][Full Text] [Related]
19. The influence of pravastatin and atorvastatin on markers of oxidative stress in hypercholesterolemic humans.
Ky B; Burke A; Tsimikas S; Wolfe ML; Tadesse MG; Szapary PO; Witztum JL; FitzGerald GA; Rader DJ
J Am Coll Cardiol; 2008 Apr; 51(17):1653-62. PubMed ID: 18436117
[TBL] [Abstract][Full Text] [Related]
20. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
